- Home
- PETS vs BNTC Comparison
PETS vs BNTC Comparison
Compare PETS & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- BNTC
- Stock Information
- Founded
- PETS 1996
- BNTC 1995
- Country
- PETS United States
- BNTC United States
- Employees
- PETS N/A
- BNTC N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- BNTC Health Care
- Exchange
- PETS Nasdaq
- BNTC Nasdaq
- Market Cap
- PETS 58.9M
- BNTC 365.1M
- IPO Year
- PETS N/A
- BNTC N/A
- Fundamental
- Price
- PETS $2.81
- BNTC $13.70
- Analyst Decision
- PETS Sell
- BNTC Strong Buy
- Analyst Count
- PETS 1
- BNTC 5
- Target Price
- PETS $3.20
- BNTC $26.00
- AVG Volume (30 Days)
- PETS 92.2K
- BNTC 36.4K
- Earning Date
- PETS 11-05-2025
- BNTC 11-13-2025
- Dividend Yield
- PETS N/A
- BNTC N/A
- EPS Growth
- PETS N/A
- BNTC N/A
- EPS
- PETS 0.02
- BNTC N/A
- Revenue
- PETS $247,010,000.00
- BNTC N/A
- Revenue This Year
- PETS N/A
- BNTC N/A
- Revenue Next Year
- PETS N/A
- BNTC N/A
- P/E Ratio
- PETS $163.80
- BNTC N/A
- Revenue Growth
- PETS N/A
- BNTC N/A
- 52 Week Low
- PETS $2.72
- BNTC $8.20
- 52 Week High
- PETS $6.85
- BNTC $17.15
- Technical
- Relative Strength Index (RSI)
- PETS 38.06
- BNTC 56.87
- Support Level
- PETS $2.98
- BNTC $13.30
- Resistance Level
- PETS $3.08
- BNTC $14.05
- Average True Range (ATR)
- PETS 0.11
- BNTC 0.55
- MACD
- PETS -0.02
- BNTC 0.01
- Stochastic Oscillator
- PETS 19.15
- BNTC 63.53
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.